The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women

¹ Centro de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa, Veracruz, Mexico
² AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, USA
³ Palatin Technologies, Inc., Cranbury, New Jersey, USA
⁴ Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia, USA

Author for correspondence: Amama Sadiq, MD, MPH Email: [email protected]

Received June 03, 2020

Accepted November 20, 2020

CNS Spectrums 27(3):p 281-289, June 2022. | DOI: 10.1017/S109285292100002X